Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
AUTOR(ES)
Ghetie, Maria-Ana
FONTE
The National Academy of Sciences of the USA
RESUMO
Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we demonstrate that mAbs which have little or no signaling activity—i.e., anti-CD19, CD20, CD21, CD22 and Her-2—can become potent antitumor agents when they are converted into IgG–IgG homodimers. The homodimers exert antigrowth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and, in the case of the anti-CD19 mAb, did not require an Fc portion. These results offer the possibility that homodimers of other tumor-reactive mAbs which have little antitumor activity as monomers might be potent, antitumor agents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=23852Documentos Relacionados
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
- CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer
- Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination
- A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
- Capacity of Mycobacterium avium isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor.
